Celltinel
Celltinel is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Celltinel.
Frequently Asked Questions
Who founded Celltinel?
Celltinel was founded by Amit Bohensky (Founder).
Celltinel is a company.
Key people at Celltinel.
Celltinel was founded by Amit Bohensky (Founder).
Celltinel was founded by Amit Bohensky (Founder).
Key people at Celltinel.
Celltheon is a San Francisco Bay Area-based biopharmaceutical company specializing in custom cell line development, complex protein expression, and end-to-end solutions for drug development and manufacturing.[1][3][5] It serves biotech, pharma, and CDMO clients by addressing challenges in producing antibodies and difficult-to-express proteins, offering services like developability optimization, analytical characterization, GLP bioproduction, and scale-up to accelerate clinical timelines.[3][5] With platforms such as OmniCHO™ for rapid transient expression, Goldilocks™ Transposase for high-titer stable cell lines (up to 10–15 g/L), and SUPER CELL™ CHOK1 for biosimilars, Celltheon has supported over 100 global clients on 1000+ proteins with a 100% success rate, enabling gram-scale production in weeks.[3][5]
Founded in 2012 and currently in the Debt/Alive stage with $200K raised, Celltheon demonstrates steady growth through partnerships, such as with Scorpius BioManufacturing, to secure client supply chains and IP while bridging early development to GMP manufacturing.[1][3]
Celltheon was founded in 2012 in Union City, California, as a biotech firm focused on overcoming protein expression hurdles in biotherapeutics development.[1][3][5] While specific founder details are not publicly detailed in available sources, the company's team leverages decades of combined experience in protein expression technologies, evolving from custom services to a comprehensive suite of patented platforms.[3]
Key milestones include developing industry-leading tools like OmniCHO™, Goldilocks™, and SUPER CELL™, which have enabled work on 1000+ proteins for 100+ clients.[3][5] A pivotal partnership with Scorpius highlighted its role in early-stage biotechs, allowing seamless transfer of stable cell lines to GMP facilities and emphasizing responsive, high-quality services for researchers.[1]
Celltheon's strengths lie in its integrated technology platforms and service model, setting it apart in the biopharma CDMO space:
These enable cost reduction, timeline acceleration, and supply chain security via U.S.-based operations and partnerships.[1]
Celltheon rides the wave of biologics and biotherapeutics expansion, where protein expression bottlenecks hinder 70-80% of preclinical programs amid rising demand for complex antibodies, bispecifics, and biosimilars.[3] Its timing aligns with post-pandemic biomanufacturing shortages and a push for resilient, domestic CDMO capacity, as seen in its Scorpius collaboration to de-risk early development for U.S.-based GMP scaling.[1]
Market forces like surging cell/gene therapy needs and regulatory pressures for faster clinical progression favor its platforms, which streamline from discovery to manufacturing.[2][5][6] By serving diverse clients, Celltheon influences the ecosystem through tech transfer, IP protection, and enabling smaller players to compete, ultimately speeding biotherapeutics to patients more affordably.[1][3]
Celltheon is poised for expansion as biopharma demands efficient, high-titer expression for next-gen modalities like ADCs and multi-specifics, potentially scaling via more CDMOs and platform licensing.[3][5][6] Trends in AI-driven protein design and modular manufacturing will amplify its role, with opportunities in cash flow positivity through revenue growth and market share in the $20B+ CDMO space.[1]
Its influence may evolve toward global partnerships and biosimilar dominance, building on a flawless track record to solidify as a go-to for complex biologics—keeping programs moving forward amid industry hurdles.[3]